BRIEF-Helix Biopharma Q2 loss per share C$0.03
March 16 (Reuters) - Helix Biopharma Corp :
* Helix Biopharma Corp. announces second quarter fiscal 2016 results
* Cash reserves as at January 31, 2016 insufficient to see current research and development initiatives through to completion
* Management considers securing additional funds, expected to be through issuance of equity securities of company
* Q2 loss per share C$0.03
* Cash reserves as at Jan 31, 2016, are insufficient to meet anticipated cash needs for working capital and capital expenditures through next 12 months Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.